Oncology News Central Peer-Spectives

William Gradishar, MD, talks with Robert Figlin, MD, about breast cancer research highlights from the 2022 American Society of Clinical Oncology Annual Meeting, including results from DESTINY-Breast04 and new data on CDK4/6 inhibitors from the PALOMA-2 and MAINTAIN trials.

Michael B. Atkins, MD, talks with Robert A. Figlin, MD, about the importance of sequencing therapies for patients with BRAF-positive metastatic melanoma. Data from the DREAMSeq trial, which Dr Atkins updated at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, show a significant survival advantage at two years for patients who receive ipilimumab plus nivolumab prior to receiving a BRAF/MEK inhibitor. But not all patients fit that paradigm. Listen as Dr Atkins shares which patients he starts on immunotherapy and when he thinks is the best time for crossover to a targeted agent.

Listen in as Roy Herbst, MD, PhD, shares with Robert Figlin, MD, how he approaches treatment for patients with early-stage non-small cell lung cancer after the ADAURA and CHECKMATE-816 trials. They discuss different factors that influence use of adjuvant and neoadjuvant treatments, including stage, EGFR mutation status, and PD-L1 status.